No Data
Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Mizuho Securities Remains a Buy on Relmada Therapeutics (RLMD)
Russell U.S. Indexes Shift to Semi-annual Reconstitution From Annual, IREN in Russell 1000
Relmada Therapeutics Joins Russell 2000 and Russell 3000 Indexes
H.C. Wainwright Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $12
Analysts Are Bullish on These Healthcare Stocks: TScan Therapeutics (TCRX), Relmada Therapeutics (RLMD)
152498972 : I chickened out early lost out